FOSTER CITY, Calif.--(BUSINESS WIRE)--OXIS International, Inc. (OTCBB: OXIS) (Nouveau Marché: OXIS) (FWB: OXI) commented today on an earlier announcement by Alteon (Amex: ALT) that BXT-51072 (ALT-2074), a compound that OXIS developed and subsequently licensed to Alteon, has been shown to significantly reduce the myocardial damage in a diabetic mouse heart injury model.
